Back HBV Prevention

HBV Prevention

HIV Controllers Respond Better to Hepatitis B Vaccine

HIV positive natural controllers who maintain undetectable or low viral load without antiretroviral therapy (ART) are more likely to achieve adequate response to hepatitis B virus (HBV) vaccination and have improved survival, according to a study published in the August 21 edition of the open-access journal PLoS ONE.

alt

Read more:

EASL 2014: Sci-B-Vac Bests Engerix-B for Preventing Mother-to-Child HBV Transmission

An investigational vaccine known as Sci-B-Vac given to babies born to women with hepatitis B was more effective at preventing HBV infection than the widely used Engerix-B vaccine, according to a report at the EASL International Liver Congress this month in London.

alt

Read more:

Lack of Sleep May Compromise Hepatitis B Vaccine Response

People who got less than 6 hours of sleep per night showed significantly reduced antibody responses after hepatitis B virus (HBV) vaccination, a finding that may shed light on the well-known association between poor sleep and increased susceptibility to infectious disease, researchers reported in the August 1, 2012, issue of Sleep.alt

Read more:

CDC Updates Guidance for Hepatitis B Vaccination of Health-care Providers

The U.S. Centers for Disease Control and Prevention (CDC) has published updated guidance for evaluating and ensuring protection against hepatitis B virus (HBV) for health-care workers, as well as post-exposure prophylaxis recommendations for those without adequate vaccine protection.

alt

Read more:

FDA Will Review New Dynavax Hepatitis B Virus Vaccine

The U.S. Food and Drug Administration (FDA) has indicated that it will review for approval a new hepatitis B vaccine known as Heplisav.alt

Read more:

AASLD 2013: Hepatitis B Vaccine Protection Lasts at Least 30 Years

Hepatitis B vaccination provides long-term protection through 30 years for a majority of recipients, and more than 90% were protected with either initial immunization or a booster, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC.

alt

Read more:

U.S. Agencies Recommend Blunt Suture Needles to Reduce Risk of Viral Hepatitis and HIV

In late May, U.S. agencies concerned with worker health and safety issued a joint advisory recommending that healthcare personnel should use blunt-tip suture needles as an alternative to standard suture needles for stitching muscle and connective tissue, in order to decrease the risk of needle-stick injuries that could transmit blood-borne diseases such as hepatitis B, hepatitis C, and HIV.alt

Read more:

IDWeek 2013: Tenofovir May Help Prevent Mother-to-child Hepatitis B Transmission

Taking tenofovir (Viread) during the final months of pregnancy may provide extra protection against perinatal transmission of hepatitis B virus (HBV), along with immunization of the infant, according to a late-breaker presentation the Second IDWeek conference last week in San Francisco.alt

Read more:

CDC Advisory Committee Recommends Hepatitis B Vaccine for People with Diabetes

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) last week recommended that adults up to age 60 with diabetes should be vaccinated against hepatitis B virus (HBV), as this group has a higher risk of infection compared with the general population.alt

Read more:

FDA Rejects Heplisav Hepatitis B Vaccine Seeking More Safety Data

The U.S. Food and Drug Administration (FDA) has declined to approve Dynavax Technologies' experimental hepatitis B virus (HBV) vaccine candidate with a toll-like receptor 9 adjuvant, stating it wants to see further data on safety in adults including seniors, the company announced this week.

alt

Read more:

ICAAC 2011: Double Dose of Hepislav Works as Well as 3 Doses of Standard HBV Vaccine

Two injections of Dynavax's investigational Heplisav hepatitis B virus (HBV) vaccine protected adults over age 40 as well as the standard regimen consisting of 3 doses of the Engerix-B vaccine given over 6 months, researchers reported at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.alt

Read more:

HIV+ Less Likely to Respond to Hepatitis B Vaccine, but More Shots Increase Protection

Adults in Kenya responded as well overall to hepatitis B vaccination as people in high-income countries. People with HIV had poorer response, but this could be mostly overcome with repeated doses, according to a study described in the February 1, 2013, Journal of Infectious Diseases.

alt

Read more:

Additional HBV Vaccine Dose Offers More Protection for People with HIV

Two alternative dosing schedules of hepatitis B virus (HBV) vaccination led to higher levels of protection than the standard 3-dose schedule. alt

Read more:

Teens Vaccinated Against Hepatitis B as Infants May Lose Immunity

Adolescents who received combined active-passive hepatitis B virus (HBV) immunization soon after birth may lose "immunological memory" that protects them from future infection, with the HBeAg status of the mother playing a key role, researchers reported in the January 2013 issue of Hepatology.

alt

Read more:

Hepatitis B Vaccination Dramatically Lowers Prevalence among U.S. Children

Children and adolescents in the U.S. today have a very low likelihood of hepatitis B virus (HBV) infection thanks to widespread vaccination, according to an epidemiological study described in the March 1, 2011, Annals of Internal Medicine. Many adults remain vulnerable, however, underlining the importance of vaccination for at-risk groups. alt

Read more:

FDA Committee Says Heplisav Hepatitis B Vaccine Is Effective, but Safety Data Inadequate

A U.S. Food and Drug Administration (FDA) committee last month concurred that Dynavax's investigational hepatitis B virus (HBV) vaccine Heplisav was effective in preventing infection, but a majority thought there was not enough data to show whether the vaccine is safe.

alt

Read more:

Hepatitis B Therapeutic Vaccine Appears Safe and Stimulates Immune Response

In late December, Dynavax Technologies reported findings from a small early clinical trial showing that its investigational hepatitis B virus (HBV) therapeutic vaccine DV-601 -- intended to help control the virus in people already infected, rather than prevent infection -- was well tolerated and produced immunological and virological responses at all dose levels. Larger studies are needed, however, to show whether the vaccine is clinically effective.

Read more:

ICAAC 2012: Hepatitis B Vaccine Effective Long-term, but Some Lose Protection after 15 Years

Nearly all children who received 3 doses of the Engerix-B hepatitis B vaccine achieved protective immunity, but about 20% fell below the protective antibody threshold by year 15 and could benefit from a booster shot, Canadian researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco. alt

Read more:

Telbivudine and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis B Transmission

Treatment with the nucleoside analog telbivudine (Tyzeka) and birth by elective Cesarean section both reduced the likelihood of hepatitis B virus (HBV) transmission from mothers to infants during pregnancy and delivery, according to 2 separate studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. Emergency Cesarean delivery, however, was associated with a trend toward increased transmission risk.

Read more:

Hepatitis B Rates Higher than Expected among Gay Men, Drug Users, Vaccinated Babies

altAn unexpectedly high proportion of gay/bisexual men and injection drug users develop chronic hepatitis B rather than clearing the infection, Amsterdam researchers reported in the September 2012 Journal of Hepatology. Other recent studies found that more than one-quarter of children born to mothers with hepatitis B showed evidence of "occult" HBV infection despite vaccination at birth, and that some individuals vaccinated as children may still show evidence of infection as adults.

Read more:

Nearly 20% of New Hepatitis B Infections May Occur in Healthcare Settings

As many as 1 in 5 cases of acute hepatitis B virus (HBV) infection in the U.S. may be attributable to exposure in healthcare settings, especially long-term care facilities, according to research presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.

Read more: